Trial · NCT04810182
Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS
NCT04810182, Completed, Istituto Oncologico Veneto IRCCS
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS. Trials, record NCT04810182. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04810182
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS
- NCT number
- NCT04810182
- Status
- Completed
- Enrollment
- 192 participants, actual
- Lead sponsor
- Istituto Oncologico Veneto IRCCS
- Conditions
- Glioblastoma Multiforme
- Interventions
- Regorafenib 40 MG Oral Tablet [STIVARGA]
- First posted
- 2021-03-22
- Last updated
- 2024-02-08
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival (OS) | From the enrolment date to the date of death, for any cause, or to the last follow-up, assessed up to 18 months | Overall Survival is defined as the time from date of enrolment to the date of death due to any cause |
| Secondary | Progression free survival (PFS) | From the date of enrolment to the date of disease progression or to the date of death, assessed up to 18 months | from the date of enrolment to the date of disease progression determined using RANO criteria or to the date of death, whichever occurs first. |
| Secondary | Objective response rate (ORR) | Approximately 24 months | As percentage of patients achieving a complete response plus partial response |
| Secondary | Disease control rate (DCR) | Approximately 24 months | As percentage of patients achieving a complete response plus partial response plus stable disease. |
| Secondary | Toxicity (Graded according to the NCI-Common Terminology Criteria for Adverse Events-CTCAE v5.0) | From the start of Regorafenib treatment up to 30 days after the end of treatment | Toxicity during the treatment will be recorded and graded according to the NCICommon Terminology Criteria for Adverse Events (CTCAE) v.4.. , related to severity of the adverse event from Grade 1 to Grade 5 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04810182
GET https://conductscience.org/api/trials/v1/NCT04810182/registered